Skip to main content
padlock icon - secure page this page is secure

Molecular Targeting of Liposomal Nano-Particles to Lymphatic System

Buy Article:

$68.00 + tax (Refund Policy)

Conventional liposomal drug delivery has been associated with obvious limitations, such as a rapid absorption by the recticulo-endothelial system in the liver and spleen, a short circulation time and a low therapeutic efficacy. Various modifications of liposomal drugs have been developed to prolong the duration of actions of the drugs at target sites, reduce its adverse effects and increase therapeutic index of drugs such as polymeric conjugation and polymeric fixation on the surface of a liposome. The lymphatic system is an important highway to spread the metastasis of most human cancers including breast, colon, and lung, ovarian and prostate. To eradicate those metastatic cancer cells from the lymphatic system, several efforts have been made to develop new and efficient lymphatic targeting drug delivery systems in order to achieve a high initial lymphatic uptake and lymph node localization. Recently, molecule targeting of liposome to lymphatic system may enhance therapeutic efficacy by improving the initial lymphatic uptake and the lymph nodal retention of liposomes such as the ligand-receptor and antibodies binding on the surface of liposome. This article aims to review the emerging liposomal drug, which is targeting the lymphatic system. The significant factors associated with targeting liposomal drugs will also be discussed in more detail in this review.

No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Adriamycin; Cholesterol; Dicetylphosphate; Egg phosphatidylcholine; Egg-phosphatidylglycerol; Injected dose; Liposome; Phosphatidylcholine; Phosphatidylserine; Stealth liposome; Vascular endothelial growth factors; auxiliary lymph node; biotin/avidin-liposome; bloodstream; camptothecin; chemotherapy; dendrimers; dipalmitoyl-phosphatidylcholine (DPPC); doxorubicin; epidermal growth factor-2; human immunodeficiency virus; immune system; immunoliposome; liposomal; lymphatic sys-tem; lymphatic system; metastasis; monoclonal antibodies; nano-crystals; phacocytosis; phosphatidylserine; phospholipid liposome; radiotherapy; targeted drug delivery system

Document Type: Research Article

Publication date: February 1, 2011

More about this publication?
  • Current Cancer Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular drug targets involved in cancer, e.g. disease specific proteins, receptors, enzymes, genes.
    Each issue of the journal contains a series of timely in-depth reviews written by leaders in the field covering a range of current topics on drug targets involved in cancer.
    As the discovery, identification, characterization and validation of novel human drug targets for anti-cancer drug discovery continues to grow; this journal has become essential reading for all pharmaceutical scientists involved in drug discovery and development.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more